Table 2. Therapeutic strategies targeting AHR and AR signaling.

AHR: Aryl Hydrocarbon Receptor; AR: Androgen Receptor; ADT: Androgen Deprivation Therapy.

Therapeutic Approach	Target Pathway	Potential Benefits	Population Focused
AHR Antagonists	AHR Signaling	Inhibit pro-tumorigenic effects of AHR, potentially reducing aggressiveness of prostate cancer.	African American men with high AHR activity.
AR Signaling Inhibitors (e.g., ADT)	AR Signaling	Reduce AR-driven tumor growth, though resistance may occur in high AR activity cases.	Patients with high AR activity, particularly African American men.
Combination Therapy (AHR and AR)	Both AHR and AR	Address both signaling pathways to combat aggressive prostate cancer forms and overcome resistance to ADT.	High-risk populations with genetic predispositions for high AHR and AR activity.